CDK12突变型前列腺癌的单中心临床病理特征分析

Analysis of the clinicopathological characteristics of CDK12-mutant prostate cancer in a single center

目的探讨细胞周期依赖性蛋白12(CDK12)突变型前列腺癌的临床病理特征、突变类型及治疗方式。方法报告10例CDK12突变型前列腺癌患者的临床病理特征、基因检测结果和随访资料,复习相关文献并进行讨论。结果10例患者平均确诊年龄为(66.60±6.80)岁,平均血清前列腺特异性抗原为652.19 ng/ml,并且穿刺Gleason评分均≥8分,8例患者确诊时已出现远处转移。此外,6例患者的CDK12突变发生在去势抵抗阶段。结论CDK12突变型前列腺癌恶性程度较高且易进展至去势抵抗,该部分患者可能会从铂类化疗、聚ADP核糖聚合酶(PARP)抑制剂或免疫治疗中获益。

Objective To investigate the clinicopathological characteristics,types of mutation and treatment methods of cell cycle-dependent kinase 12(CDK12)-mutant prostate cancer(PCa).Methods The clinicopathological characteristics,gene mutation results and follow-up data of 10 patients with CDK12-mutant PCa were reported,and the related literature was reviewed and discussed.Results The mean age of the 10 patients with a definite diagnosis was(66.60±6.80)years,and their mean serum prostate-specific antigen was 652.19 ng/ml,and their Gleason scores of puncture were more than or equal to 8 points.Of the 10 patients,eight had distant metastasis at the time of diagnosis.In addition,CDK 12 mutation occurred in castration-resistant stage in 6 patients.Conclusion Patients with CDK12-mutant PCa,which has a high degree of malignancy and is prone to castration-resistant stage,may benefit from platinum-based chemotherapy,poly ADP-ribose polymerase(PARP)inhibitors or immunotherapy.